GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases
9 days ago - GlobeNewsWire
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topl...
19 days ago - GlobeNewsWire
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Other symbols: OSAPBLASINT
4 weeks ago - Benzinga
GRI Bio Announces Pricing of $5.5 Million Public Offering
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
7 weeks ago - GlobeNewsWire
GRI Bio Announces Reverse Stock Split
GRI's common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Compan...
2 months ago - GlobeNewsWire
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
Other symbols: ALVRIBIOVYNE
2 months ago - Benzinga
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, lim...
3 months ago - GlobeNewsWire
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only tw...
4 months ago - GlobeNewsWire
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024
4 months ago - GlobeNewsWire
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
Data presented at the 7 th Annual Antifibrotic Drug Development (AFDD) Summit Company's lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells ea...
5 months ago - GlobeNewsWire
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients
5 months ago - GlobeNewsWire
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research
5 months ago - GlobeNewsWire
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
- Live moderated webcast with Marc Hertz, Chief Executive Officer of GRI Bio on Tuesday, October 24 th at 11:00 AM ET
5 months ago - GlobeNewsWire
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting
6 months ago - GlobeNewsWire
September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly Disease
LA JOLLA, CA / ACCESSWIRE / September 29, 2023 / September is Pulmonary Fibrosis Awareness Month - a time dedicated to raising public consciousness and understanding about this devastating lung diseas...
6 months ago - Accesswire
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell mod...
7 months ago - GlobeNewsWire
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?
LA JOLLA, CA / ACCESSWIRE / September 1, 2023 / Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the ...
7 months ago - Accesswire
GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign
La Jolla, California--(Newsfile Corp. - August 29, 2023) - GRI Bio, Inc. (NASDAQ: GRI), a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer T (NKT) cel...
7 months ago - Newsfile Corp
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
LA JOLLA, CA / ACCESSWIRE / August 25, 2023 / Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various ...
7 months ago - Accesswire
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU
7 months ago - GlobeNewsWire
JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series
GRI Bio kicks-off the series by explaining what recently published preclinical data on its GRI-0803 Lupus development program means for its overall advancement FRENCHTOWN, NJ / ACCESSWIRE / August 16,...
7 months ago - Accesswire
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rapidly advancing c linical pipeline across multiple high-value i nflammatory, f ibrotic and a utoimmune d iseases
7 months ago - GlobeNewsWire
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
Data p resented at The Autoimmunity Conference h osted by the Federation of American Societies for Experimental Biology (FASEB)
8 months ago - GlobeNewsWire
JTC Team to Host Two Virtual Investor Spotlight Events on Thursday, July 27th
Live video webcasts with moderated interactive discussion with American Resources Corporation (NASDAQ:AREC) and GRI Bio (NASDAQ:GRI), respectively FRENCHTOWN, NJ / ACCESSWIRE / July 26, 2023 / JTC Tea...
Other symbols: AREC
8 months ago - Accesswire
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27 th at 1:00 PM ET
8 months ago - GlobeNewsWire
